Results 51 to 60 of about 358,441 (297)
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy [PDF]
, 2019 The therapeutic management of recurrent malignant gliomas (MGs) is not determined. Therefore, the efficacy of a multimodal approach and a combination systemic therapy was investigated.
Bianco, Vincenzo +10 more
core +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Gliosarcoma Transforming from Giant Cell Glioblastoma: A Case Report and Review of the Literature
Haseki Tıp Bülteni, 2019 Giant cell glioblastoma and gliosarcoma are rare histological variants of glioblastoma multiforme. These are WHO Grade IV astrocytic tumors. While giant cell glioblastoma can be seen at younger age, gliosarcoma typically presents at age 40-60 years ...
Elife Kımıloğlu +3 more
doaj +1 more source
Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2. [PDF]
PLoS ONE, 2012 Glioblastoma constitutes the most aggressive and deadly of brain tumors. As yet, both conventional and molecular-based therapies have met with limited success in treatment of this cancer.
Julie Dwyer +8 more
doaj +1 more source
The newfound relationship between extrachromosomal DNAs and excised signal circles
FEBS Letters, EarlyView.Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley +1 more source
Pan African Medical Journal, 2014 Glioblastoma represents 15%-20% of all intracranial tumors and approximately 50 % of gliomas in adults. Although capable of arising anywhere in the central nervous system, these tumors mainly present as a frontotemporal lesion (63%) of the cerebral cortex.
Cherkaoui Mandour, Brahim El Mostarchid
openaire +3 more sources
Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. [PDF]
, 2015 The standard of care for newly diagnosed glioblastoma (GBM) is surgery, then radiotherapy (RT) with concurrent temozolomide (TMZ), followed by adjuvant TMZ. We hypothesized patients with low diffusivity measured using apparent diffusion coefficient (ADC)
Chang, Warren +9 more
core +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Scientific ReportsThe blood–brain barrier (BBB) is a highly selective barrier that strictly controls the passage of substances and cells into the brain, protecting it from potential harm while preserving homeostasis.
Francesco Saverio Sica +11 more
doaj +1 more source
The Role of NKT Cells in Glioblastoma
Cells, 2021 Glioblastoma is an aggressive and deadly cancer, but to date, immunotherapies have failed to make significant strides in improving prognoses for glioblastoma patients.
Emily E. S. Brettschneider +1 more
doaj +1 more source